Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
The effect of sertraline on methadone plasma levels in methadone-maintenance patients
Autore:
Hamilton, SP; Nunes, EV; Janal, M; Weber, L;
Indirizzi:
New York State Psychiat Inst, New York, NY 10032 USA New York State Psychiat Inst New York NY USA 10032 New York, NY 10032 USA Columbia Univ, Coll Phys & Surg, Dept Psychiat, New York, NY 10027 USA Columbia Univ New York NY USA 10027 Dept Psychiat, New York, NY 10027 USA
Titolo Testata:
AMERICAN JOURNAL ON ADDICTIONS
fascicolo: 1, volume: 9, anno: 2000,
pagine: 63 - 69
SICI:
1055-0496(200024)9:1<63:TEOSOM>2.0.ZU;2-0
Fonte:
ISI
Lingua:
ENG
Soggetto:
HUMAN LIVER-MICROSOMES; DEPRESSIVE-DISORDERS; CYTOCHROME-P450 3A4; ADDICTS; FLUOXETINE; METABOLISM; INHIBITION; PHARMACOKINETICS; ANTIDEPRESSANTS; FLUVOXAMINE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Social & Behavioral Sciences
Citazioni:
33
Recensione:
Indirizzi per estratti:
Indirizzo: Hamilton, SP New York State Psychiat Inst, Unit 28,1051 Riverside Dr, New York, NY 10032 USA New York State Psychiat Inst Unit 28,1051 Riverside Dr New York NY USA 10032
Citazione:
S.P. Hamilton et al., "The effect of sertraline on methadone plasma levels in methadone-maintenance patients", AM J ADDICT, 9(1), 2000, pp. 63-69

Abstract

The authors examine methadone plasma levels in 31 depressed methadone-maintained opiate addicts enrolled in la 12-week placebo-controlled, double-blind study of sertraline. Between baseline and week 6, patients out sertraline showed a mean increase in methadone plasma level/dose (P/D) ratio of 26% (SD = 43% range -32% to +118%), while patients on placebo showed a mean decrease of 16% (SD = 27%) range -62% to +50%. This difference was significant(p < 0.02). The sertraline and placebo groups did not differ in reported side effects or methadone dose adjustments. Between weeks 6 and 12, methadone P/D in the sertraline group decreased back towards baseline and the treatment groups did not differ significantly at week 12. The results suggest sertraline may produce a modest increase in methadone serum levels over the first six weeks of treatment. Depression and anxiety disorders are common inmethadone-maintained patients. Serotonin uptake inhibitors are attractive choices for treatment due to their low toxicity and low abuse potential; but these agents variously inhibit isoenzymes responsible for the metabolism of methadone. Clinicians treating: depressed or anxious methadone patients with second-generation antidepressants should monitor for clinical signs ofincreased or decreased methadone levels and consider monitoring serum methadone levels.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 22/01/20 alle ore 12:57:47